Mar 10, 2022 4:01 pm EST Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 03, 2022 9:15 am EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
Mar 02, 2022 9:00 am EST Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
Jan 25, 2022 5:00 am EST Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
Dec 13, 2021 9:15 am EST Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Nov 12, 2021 9:15 am EST Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
Nov 09, 2021 4:05 pm EST Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 02, 2021 4:05 pm EDT Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
Sep 24, 2021 7:00 am EDT Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
Sep 22, 2021 4:05 pm EDT Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences